how long will semaglutide be on fda shortage list ends as sets deadline for compounders Novo Nordisk, FDA Score Win

Regulatory and safety status: Epitalon is currently awaiting FDA review

Peptides for weight loss can be safe when used under the guidance of a healthcare professional and in accordance with proper dosing and administration protocols

Hormonal context: Adequate testosterone supports libido, NO synthase expression, PDE5 responsiveness, and mood/energy

Exercise volume (47 days per week, with 35 sessions of resistance training) substantially above population norms

Diabetic neuropathy: cutting-edge research and future directions

Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years News provided by Prime Therapeutics LLC Jun 25, 2025, 10:00 ET Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)